2. Academic Validation
  3. SIRT1 activator E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression

SIRT1 activator E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression

  • Atherosclerosis. 2018 Jul;274:172-181. doi: 10.1016/j.atherosclerosis.2018.04.039.
Tingting Feng 1,  Peng Liu 2,  Xiao Wang 2,  Jinque Luo 2,  Xuan Zuo 2,  Xinhai Jiang 2,  Chang Liu 2,  Yongzhen Li 2,  Ni Li 3,  Minghua Chen 2,  Ningyu Zhu 2,  Xiaowan Han 2,  Chao Liu 2,  Yanni Xu 4,  Shuyi Si 5
Affiliations

Affiliations

  • 1 NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, 100050, China; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
  • 2 NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, 100050, China.
  • 3 NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, 100050, China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS & PUMC, Beijing, 100050, China.
  • 4 NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, 100050, China. Electronic address: xuyanniwendeng@hotmail.com.
  • 5 NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, 100050, China. Electronic address: sisyimb@hotmail.com.
PMID: 29787963 DOI: 10.1016/j.atherosclerosis.2018.04.039
Abstract

Background and aims: Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent protein deacetylase. Recent studies have demonstrated that enhancing SIRT1 expression or activity may modulate Cholesterol and lipid metabolism. However, pharmacological and molecular regulators for SIRT1 are scarce. Here, we aimed to find novel small molecule modulators of SIRT1 to regulate Cholesterol and lipid metabolism.

Methods: A high-throughput screening assay was established to identify SIRT1 activators. Surface plasmon resonance and immunoprecipitation were performed to confirm the interaction of E1231 with SIRT1. Cholesterol assay was performed to demonstrate the in vitro effect of E1231. The in vivo effect of E1231 was evaluated in experimental models.

Results: E1231, a piperazine 1,4-diamide compound, was identified as a SIRT1 Activator with EC50 value of 0.83 μM. E1231 interacted with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα). E1231 increased ATP-binding cassette transporter A1 (ABCA1) expression in RAW 264.7 cells dependent on SIRT1 and LXRα. E1231 promoted Cholesterol efflux and inhibited lipid accumulation in RAW 264.7 cells via SIRT1 and ABCA1. In the golden hamster hyperlipidemia model, E1231 treatment decreased total Cholesterol and triglyceride levels in both serum and the liver, while increased Cholesterol content in feces. Moreover, E1231 increased ABCA1 and SIRT1 protein expression in the liver. In apoE-/- mice, E1231 treatment reduced atherosclerotic plaque development compared with untreated apoE-/- mice.

Conclusions: We identified a novel SIRT1 Activator E1231 and elucidated its beneficial effects on lipid and Cholesterol metabolism. Our study suggests that E1231 might be developed as a novel drug for treating atherosclerosis.

Keywords

ABCA1; Cholesterol and lipid metabolism; LXRα; SIRT1.

Figures
Products